GlaxoSmithKline (GSK) has launched its Herpes Zoster vaccine, Shingrix (RZV), in Malaysia. This non-live, recombinant subunit adjuvanted vaccine is intended for adults aged 50 and over, and those at increased risk of shingles and post-herpetic neuralgia.
GSK shingles vaccine
Shingrix is administered in two doses and has shown up to 97% efficacy in preventing shingles in clinical trials. The vaccine aims to address the painful effects of shingles, which result from the reactivation of the varicella zoster virus. GSK’s Country Medical Director, Dr. Alap Gandhi, emphasized the importance of the vaccine in reducing the burden of this disease.
Read More Business News
Leave a Reply
You must be logged in to post a comment.